Equels Thomas K 4

What Happened
Thomas K. Equels, CEO, President and a director of AIM ImmunoTech (AIM), reported converting derivative (preferred) securities into common stock on March 12, 2026. The filing shows an acquisition of 25,000 common shares at $0.00 (total $0) via conversion, and a related reporting line showing 25 derivative shares disposed at $0.00. The transaction was a conversion (not a cash purchase or market sale).

Key Details

• Transaction date(s): 2026-03-12; Form 4 filed 2026-03-16.
• Primary conversion: +25,000 common shares acquired at $0.00 (derivative conversion).
• Additional reported line: 25 shares disposed at $0.00 (derivative).
• Shares owned after transaction: Not disclosed in the excerpt provided.
• Footnotes: F1 — Preferred shares convert at 1,000 common shares per whole preferred share (i.e., 25 preferred ➜ 25,000 common); F2 — None.
• Filing timeliness: The filing date is listed as 2026-03-16 for a 2026-03-12 transaction; no explicit late-filing code (transactionTimeliness = 'L') was provided in the excerpt.

Context
This was a conversion of preferred/derivative securities into common shares (a non-cash transaction). Conversions can reflect capitalization or restructuring mechanics rather than an economic buy/sell decision by the insider; they do not necessarily signal a change in insider sentiment. The conversion ratio (1,000:1) explains how 25 preferred shares resulted in 25,000 common shares.